"Idarubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
Descriptor ID |
D015255
|
MeSH Number(s) |
D02.455.426.559.847.562.050.200.300 D04.615.562.050.200.300 D09.408.051.059.200.300
|
Concept/Terms |
Idarubicin- Idarubicin
- 4-Desmethoxydaunorubicin
- 4 Desmethoxydaunorubicin
- 4-Demethoxydaunorubicin
- 4 Demethoxydaunorubicin
|
Below are MeSH descriptors whose meaning is more general than "Idarubicin".
Below are MeSH descriptors whose meaning is more specific than "Idarubicin".
This graph shows the total number of publications written about "Idarubicin" by people in this website by year, and whether "Idarubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2005 | 1 | 0 | 1 |
2014 | 0 | 1 | 1 |
2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Idarubicin" by people in Profiles.
-
Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):375-381.
-
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024 01; 38(1):58-66.
-
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720.
-
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022 11; 97(11):1427-1434.
-
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043.
-
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug; 8(8):e552-e561.
-
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778.
-
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.
-
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. 2019 09; 94(9):984-991.
-
Topoisomerase II inhibitors in AML: past, present, and future. Expert Opin Pharmacother. 2019 Sep; 20(13):1637-1644.